Patrick Daly

DocwireNews

Pitolisant is a selective histamine H3-receptor inverse agonist that was approved for the treatment of adult patients with narcolepsy with or without cataplexy. In an article published in The Lancet Neurology, researchers led by Yves Dauvilliers, MD, evaluated pitolisant in a cohort of pediatric patients with narcolepsy with or without cataplexy.Based on changes in Ullanlinna Narcolepsy Scale (UNS) scores, Dr. Dauvilliers and colleagues concluded pitolisant therapy improved symptoms compared with placebo in their patients. Authors noted that the UNS tool was not validated for children with narcolepsy when they began the study. A decrease in UNS total score indicated a decrease in <a href="https://www.docwirenews.com/post/establishing-daytime-sleepiness-rhythms-in-children-with-narcolepsy">excessive daytime sleepiness</a> and cataplexy.The double-blind, multicenter, phase 3, randomized, controlled trial enrolled patients aged 6 to 17 years with narcolepsy. All participants had a Pediatric Daytime Sleepiness Scale score of at least 15 and had not received psychostimulants for at least 2 weeks prior to enrollment. Additionally, patients on an anticataleptic had to be on a stable dose for at least 1 month.<h3>Pitolisant Also Valuable for Children With Narcolepsy</h3>After a 4-week screening period with a 2-week baseline period, the cohort was randomized 2:1 to pitolisant or placebo. Treatment consisted of 4 weeks of individualized up-titration of pitolisant or placebo from 5 mg to a maximum of 40 mg daily. Treatment was continued at a stable dose for 4 weeks, followed by a 1-week placebo period.The primary end point of <a href="https://clinicaltrials.gov/study/NCT02611687" target="_blank" rel="noopener">the study</a> was change in UNS total score from baseline to the end of the double-blind period in all patients who received at least 1 dose of treatment and had at least 1 baseline UNS score.A total of 110 patients (55% male; mean age, 12.9&plusmn;3.0 years), of whom 90 (82%) had cataplexy, were randomized between pitolisant (n=72) or placebo (n=38). Of these, 70 patients in the pitolisant group and 37 in the placebo group completed the double-blind period.Researchers calculated the mean adjusted difference from baseline in UNS total score was &minus;6.3 (standard error [SE], 1.1) in the pitolisant group and &minus;2.6 (SE, 1.4) in the placebo group after the double-blind period (least squares mean difference, &minus;3.7; 95% CI, &minus;6.4 to &minus;1.0; P=.007).Investigators reported treatment-emergent adverse events in 22 (31%) of 72 patients in the pitolisant group and 13 (34%) of 38 patients in the placebo group, the most common of which were headache (pitolisant, 14 [19%]; placebo, 3 [8%]) and insomnia (pitolisant, 5 [7%]; placebo, 1 [3%]).Overall, Dr. Dauvilliers and colleagues concluded that pitolisant improved narcolepsy symptoms in children with narcolepsy and had a safety profile similar to that in adult patients. The article noted an open-label follow-up is ongoing, but &ldquo;further studies are needed to confirm long-term safety.&rdquo;Find More Recent Research on <a href="https://www.docwirenews.com/page/sleep-disorders">Sleep Disorders</a> and <a href="https://www.docwirenews.com/page/neurology">Neurology</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Validating Pitolisant in Pediatric Patients With Narcolepsy

Sleep Disorders

Pitolisant improved symptoms versus placebo in children with narcolepsy with adverse events comparable to adult patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe